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e.2013.03Abstract Many rheumatologic manifestations have been associated with Hepatitis C virus (HCV)
infection including; arthralgia, myalgia, fatigue, ﬁbromyalgia, vasculitis, and sicca syndrome. The
relationship between emergence and persistence of intrahepatic or circulating B cell clonotypes
and HCV infection is still unknown. However accumulating evidences indicate that certain chemo-
kines play a critical role in providing the appropriate environment for activation and expansion of
naı¨ve lymphocytes, one of these chemokines is B cell-attracting chemokine-13 (CXCL13).
CXCL13 is a major regulator of B-cell trafﬁcking. This study evaluates circulating levels of
CXCL13 protein in chronically HCV-infected Egyptian patients compared with healthy controls
and its association with articular synovial hypertrophy. Rheumatic manifestations were present
in 85% of patients; included fatigue (20%), arthralgia (the commonest manifestation) (65%), ﬁbro-
myalgia (22%), myalgia (37%), Rayunad’s phenomenon (10%), peripheral neuropathy and arthri-
tis (2.5%), and tendenitis (7.5). Cryoglobulins recorded in this study were of type II & III mixed
cryoglobulins (MC) positive in 25% all of which showed positive rheumatoid factor (RF). Signif-
icant low levels of C3 and C4 were reported in the patient group. CXCL13 serum levels were sig-
niﬁcantly high in the patient group especially in the MC positive group compared to controls. The(E.A. El-attar).
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356 E.A. El-attar et al.highest levels of CXCL13 were signiﬁcantly associated with rheumatologic manifestations with or
without mixed cryoglobulinemia and signiﬁcantly associated with articular synovial hypertrophy.
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Chronic liver disease is an inﬂammatory disorder recognized
with several etiologies and different pathogenetic mecha-
nisms.1 Within the inﬂamed liver there is an accumulation of
different lymphoid and myeloid cells, including T and B cells,
local activation of these cells is thought to be essential in per-
petuating chronic inﬂammatory processes and accelerating li-
ver damage. These cells frequently accumulate in the portal
tracts and organize follicle-like structures with germinal cen-
ters.2 In these sites, local differentiation of follicular dendritic
cells, plasma cells, and antibody production may occur.3
In hepatitis C virus (HCV) infection, distinct B cell expan-
sions contribute to the formation of intraportal follicle-like
structures, which have been found to inﬂuence the clinical pic-
ture that appears to be related to mixed cryoglobulinemia
(MC) and high serum levels of rheumatoid factor (RF). Circu-
lating B-cell clonotypes have also been suggested to be of he-
patic origin.4 The relationship between emergence and
persistence of intrahepatic or circulating B cell clonotypes
and HCV infection is still unknown; however accumulating
evidences indicate that certain chemokines play a critical role
in providing the appropriate environment for activation and
expansion of naı¨ve lymphocytes in response to signals deliv-
ered by antigen presenting cells.5
CXC ligand 13 (CXCL13), also known as B cell-attracting
chemokine 13 or B-lymphocyte chemoattractant, is a member
of CXC subtype of the chemokine superfamily,6 its essential
role was seen in the establishment and maintenance of lym-
phoid tissue microarchitecture,7 and it is critical for secondary
lymphoid tissue development and distribution of lymphocytes
within the microenvironment.
The primary CXCL13 receptor is CXCR5, which is a 7-
transmembrane G-protein expressed by B lymphocytes,8
follicular B helper T cells, osteoblasts, and skin derived dendritic
cells.9
CXCL13 is constitutively expressed in B cell follicles of sec-
ondary lymphoid organs, pleural and peritoneal cavities, and
in ectopic lymphoid follicles within the synovial membrane
of patients with rheumatoid arthritis.10
Many rheumatologic manifestations have been associated
with HCV infection including; arthralgia, myalgia, fatigue,
ﬁbromyalgia, vasculitis, and sicca syndrome. Arthralgia is
the most common extrahepatic manifestation and may indicate
mixed cryoglobulinemia MC.11
The aim of this study is to determine the level of the serum
CXCL13 in Egyptian patients with chronic hepatitis C infec-
tion (with or without mixed cryoglobulinemia) and to study
its association with rheumatologic manifestations.1.1. Patients and methods
This study was conducted on 40 Egyptian patients with
chronic hepatitis C infection (HCV) attending the Internal
Medicine & Rheumatology, Rehabilitation inpatient andoutpatients Departments, Ain Shams University Hospitals,
and 20 normal volunteers matched in age and sex with the
patients, serving as a control group. Consents were taken from
all subjects included in the study.
Hepatitis C infection was documented with HCV polymer-
ase chain reaction (HCV-PCR).
2. Exclusion criteria include
Patients with hepatitis B surface antigen (HBsAg) or positive
cytomegalovirus. Autoimmune hepatitis, hemochromatosis,
and alcoholic hepatitis were excluded. Patients with end stage
renal disease, diabetic patients, and patients with a history of
interferon therapy were also excluded from the study. None
of our patients or controls had known rheumatologic disease
prior to this present complain (X-ray is done routinely to ex-
clude any rheumatological problems).
All the patients and controls were subjected to the
following:
 Full medical history taking and clinical examination with
special focus on the rheumatological manifestations; mode
of onset and its duration; arthralgia, arthritis, synovial
hypertrophy, joint effusion, myalgia, tendinitis, tender
points of ﬁbromyalgia (according to the criteria of Ameri-
can College of Rheumatology (ACR) 1990), Raynaud’s
phenomenon and cutaneous vasculitis.
 Biochemical and Hematological proﬁles: total bilirubin,
alkaline phosphatase, aspartate aminotransferase (AST),
alanine aminotransferase (ALT), albumin, total protein,
creatinine, CBC and TSH and T3 & T4. (Taken from
recorded data of patients’ medical ﬁle).
 Immunological proﬁle rheumatoid factor RF, ANA, C3, C4.
 Cryoglobulins.
 Serum level of CXCL13 (ELISA) .The kit (R&D systems,
USA). The assay employed the quantitative sandwich
enzyme immunoassay technique that makes use of a mouse
monoclonal antibody against human CXCL13 precoated
onto a microplate. Human recombinant CXCL13 protein
at serial concentrations and 2-fold diluted serum samples
were pipetted into the wells to allow any CXCL13 to be
bound by immobilized antibody. After washing away
unbound substances, a mouse monoclonal antibody conju-
gated with horseradish peroxidase speciﬁcally directed
against CXCL13 protein was added to the wells. After fur-
ther washings, stabilized tetramethylbenzidine was added to
the wells and color developed in proportion to the amounts
of bound CXCL13. Quantikine kit standards were used for
the construction of standard curves. The sensitivity thresh-
old of the test was 2 pg/ml. Intra-Assay: CV < 10% and
inter Assay: CV < 12%.
 Abdominal ultrasonography (US) was done for accurate
assessment and documentation of hepatomegaly, spleno-
megaly, ascitis and liver cirrhosis.
 Musculoskeletal US was performed for selected joints
(those who presented with arthralgia or arthritis with
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(MCPs)), which was done by an Internist who is an expert
in abdominal and musculoskeletal ultrasonography, who
was ignorant to the clinical status of the examined subjects
using; Toshiba Medical System (Famio Cube) Model
SSA-520A (Fundamentals) (2b730-929 EN) with a
multifrequency 3.5–11 MHz transducer. Sector transducer
with frequency 3.5 MHz was used in abdomen examination.
Linear transducer frequency 11 MHz was used in joint
examination. The ultrasound examination was performed
in accordance to the European League against Rheumatism
(EULAR) Guidelines for musculoskeletal US in Rheuma-
tology.12 Joint effusion appears compressible, probe pres-
sure will squeeze ﬂuid into other parts of the joint and,
along with the absence of Doppler signal, distinguishes ﬂuid
from hypo or anechoic synovitis. Synovial hypertrophy is
deﬁned as a solid, non-compressible, hypoechoic tissue in
connection to joint lines or surrounding tendons. In the
absence of an effusion, synovitis is diagnosed by the pres-
ence of an abnormally thickened hypoechoic region.12
Real time US examination of individual subject was done,
and ﬁxed photos were saved electronically for further discus-
sion with the responsible rheumatologist.
2.1. Statistical analysis
IBM SPSS statistics (V. 20.0, IBM Corp., USA, 2011) was
used for data analysis. Data were expressed as Mean ± SD
for quantitative parametric measures in addition to both num-
ber and percentage for categorized data.
The following tests were done:
1. Comparison between two independent mean groups for
parametric data using Student’s t test.
2. Chi-square test to study the association between each two
variables or comparison between two independent groups
as regards the categorized data.
3. Comparison between two proportions as regards in variant
categorized data. The probability of error at 0.05 was con-
sidered sig., while at 0.01 and 0.001 are highly sig.
4. Spearman R testing association.3. Results
The results of this study revealed that the age of the patients
ranged from 17–54 years with a mean value of
40.7 ± 7.33 years, they were; 19 males (47.5%), and 21
(52.5%) females. While the control group was; 10 males
(50%) and 10 females (50%), their age ranged from 25 to
50 years with a mean value of 40 ± 7.1 years. No statistically
signiﬁcant differences were detected between the two groups
as regards age and sex. Disease duration ranged from few
months to several years as the exact onset is not reported
and all the cases were accidentally discovered.Figure 1 Distribution of different joint affection among HCV
patients.3.1. Clinical data of the patients as regards the hepatic
manifestations
Jaundice was detected in 18 patients, nine patients had lower
limb edema, fever was present in three patients (low grade ofno special pattern), two patients had cervical lymphadenopa-
thy, 14 had hepatomegaly conﬁrmed with US, eight patients
had ascites and 13 patients had splenomegaly and liver cirrho-
sis also conﬁrmed with abdominal US. Comparing these ﬁnd-
ings to controls (who did not show any of these abnormal
ﬁndings) there was a signiﬁcant statistical difference between
patients and controls as regards; jaundice, hepatomegaly and
liver cirrhosis (US ﬁndings), lower limb edema, and ascites
and a non signiﬁcant difference as regards; fever and
lymphadenopathy.
3.2. Rheumatic manifestations of patients
Disease duration of different rheumatic manifestations ranged
from 6 months–3 years. The prevalence of rheumatological
manifestation was 85% (34 patients), chronic fatigue was re-
corded in eight patients (20%), arthralgia in 26 patients
(65%) with different distributions as shown in (Fig. 1); knee
45%, small joints of the hand 35%, wrist and ankle 30%,
shoulder 20%, elbow 10%, hip & sacroiliac 2.5%. The onset
was monoarticular in 20/26 (76%), oligoarticular in 4/26
(15.3%), and polyarticular in 2/26 (7.6%). The full picture of
arthritis was documented in only one patient 2.5% (in the knee
joint). The arthralgia/arthritis they expressed was of no speciﬁc
pattern and was not associated with morning stiffness.
Myalgia of calf muscles and trapezii was reported in 15
patients (37.5%), ﬁbromyalgia was present in nine patients
(22%). Tendinitis (bicipital tendinitis) was reported in three
patients (7.5%), Achilles tendinitis in one patient (2.5%),
Raynaud’s phenomenon in four patients (10%), Sicca syn-
drome in four patients (10%) (manifested as xerophthalmia).
Peripheral neuropathy was detected in one patient (2.5%).
None of the patients had purpura or cutaneous vasculitis.
Rheumatic manifestations were not recorded in any of the
controls. A signiﬁcant statistical difference was noted between
the patient and control groups as regards; arthralgia, myalgia
(P< 0.001) and chronic fatigue and ﬁbromyalgia (P< 0.05).
Non-signiﬁcant differences as regards arthritis, tendinitis,
Raynaud’s phenomenon, Sicca syndrome and peripheral neu-
ropathy (P< 0.05) were also recorded.
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(Table 1)
This table shows a comparison between mean and standard
deviation of main laboratory data of patients and controls.
Highly signiﬁcant statistical differences were noted for total
bilirubin, AST, ALT, albumin and a non-signiﬁcant difference
for; total protein, creatinine, platelets and white blood cells.
3.4. Immunological data of the patients and controls are shown
in (Table 2)
Neither the patients nor the controls showed positive ANA.
Cryoglobulins were detected in 10 patients (25%), Rheumatoid
factor was positive in 22 patients (55%), and in one of
the controls (5%). None of the controls showed positiveTable 1 Comparison between patients and controls as regards labo
Variables Patient group n= 40 Mean
Total bilirubin (mg/dl) 2.3 ± 2.5
Alkaline phosphatise (IU/L) 140.30 ± 89.1
Aspartate aminotransferase (AST) (IU/L) 70.1 ± 50.1
Alanine aminotransferase (ALT) (IU/L) 65.1 ± 49.9
Albumine (gm/dl) 2.8 ± 0.6
Total protein (gm/dl) 8.1 ± 1.1
Serum Creatinine (mg/dl) 1.1 ± 0.4
Platelet count · 103/L 201 ± 20.1
White blood cells · 103/L 7.8 ± 3.1
Table 2 Comparison between patients and controls as regards imm
Variables Patient group n= 40
Cryoglobulins 10 25%
Rheumatoid factor 18 45%
Anti-nuclear antibodies (ANA) 0 0%
Range
Mean ± SD
Complement 3 mg/dl (40–147)
100.2 ± 25.7
Complement 4 mg/dl (8–45)
25.45 ± 8.3
Serum CXCL 13 Pg/L (72–371)
208.78 ± 60.84
Table 3 Comparison between cryoglobulin positive and negative p
Variables Group A (n= 10)
Rheumatic manifestations 8 80%
Chronic fatigue 2 20%
Arthralgia 6 60%
Arthritis 1 0%
Myalgia 5 50%
Fibromyalgia 3 30%
Tendenitis 0 0%
Sicca syndrome 4 40%
Raynaud’s phenomenon 0 0%
Peripheral neuropathy 1 10%cryoglobulins. Comparison between patients and controls,
showed a highly signiﬁcant difference as regards Rheumatoid
factor, complement 3, and level of CXCL 13 proteins, and a
signiﬁcant difference as regards cryoglobulins and complement
4, with low levels of C3 & C4 in the patient group. All the re-
corded cryoglobulins were of type II & III (mixed cryoglobu-
lins), the cryocrit percent ranged from 0.5% to 2%.
The patients’ group was further divided into two subgroups
according to the presence of cryoglobulins into group A which
included 10 patients and, group B without cryoglobulins,
which included 30 patients. Rheumatic manifestations were
present in 8/10 patients (80%). On comparing the prevalence
of rheumatic manifestations in group A & group B, there
was no statistically signiﬁcant difference (Table 3).
On comparing the laboratory data of groups A and B, there
was a highly signiﬁcant difference as regards the mean valuesratory data.
± SD Control group n= 20 Mean ± SD P Sig.
0.60 ± 0.3 P< 0.001 H.S
48 ± 12.9 P< 0.001 H.S
29.1 ± 7.8 P< 0.001 H.S
28.1 ± 9.1 P< 0.001 H.S
4.2 ± 0.4 P< 0.001 H.S
6.8 ± 0.28 P> 0.05 N.S
0.8 ± 0.2 P> 0.05 N.S
209 ± 28.3 P> 0.05 N.S
7.9 ± 2.1 P> 0.05 N.S
unological data.
Control group n= 20 P Sig.
0 0% P< 0.05 S
1 5% P< 0.001 H.S
0 0%
Range
Mean ± SD
(90–150) P< 0.001 H.S
123.1 ± 18.9
(24–45) P< 0.05 S
36.3 ± 4.1
(37–59) P< 0.001 H.S
48.11 ± 11.15
atients as regards prevalence of rheumatic manifestations.
Group B (n= 30) P Sig
26 86% P> 0.05 N.S
6 20% P> 0.05 N.S
20 66% P> 0.05 N.S
0 0% P> 0.05 N.S
10 33% P> 0.05 N.S
6 20% P> 0.05 N.S
4 13.3% P> 0.05 N.S
0 0% P> 0.05 N.S
4 13.3% P> 0.05 N.S
0 0% P> 0.05 N.S
Table 4 Comparison between US ﬁndings of cryoglobulin positive and negative patients.
Variables Total patients n= 40 Group A 10 patients Group B 30 patients Chi-square
No. % No. % No. % X2 P
Hepatomegaly 14 35 2 20 12 40 0.58 0.44
Ascitis 8 20 8 80 0 0 25.2 <0.001a
Liver cirrhosis 13 32 7 70 6 20 6.4 0.01b
a Highly signiﬁcant; P< 0.001.
b Signiﬁcant; P< 0.05.
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logical data of groups A and B there was a signiﬁcant differ-
ence as regards the presence of positive RF which was
present in 10/10 cryoglobulin positive patients (100%) versus
12 cryoglobulin negative patients (40%). CXCL 13 levels ran-
ged from 200–371 & 90–150 pg/L with a mean value of
260.45 ± 46.05 and 148.8 ± 60.74 for groups A and B, respec-
tively. This showed a highly signiﬁcant difference (P< 0.001).
Non-signiﬁcant difference was recorded for the other labora-
tory and immunological data.
3.5. Abdominal ultrasonography
Abdominal US conﬁrmed the clinical data, which showed that
14 patients had hepatomegaly (35%). Ascitis was present inFigure 2 Longitudinal ultrasound at the level of the second
metacarpophalangeal joint shows synovitis seen as low reﬂective
intra-articular tissue(A), (B) following compression with the
probe, ﬂuid is squeezed into parts of the joint so the effusion is
compressible, distinguishes it from synovitis (non-compressible).eight patients (20%), and liver cirrhosis was present in 13 pa-
tients (32%). On comparing the prevalence of hepatomegaly,
ascitis and liver cirrhosis between groups A and B, hepatomeg-
aly and ascitis for group A were signiﬁcantly higher (Table 4).
3.6. Musculoskeletal US
High frequency linear transducer 11 MHZ, was used in evalu-
ation of 26 of our patients for the presence of clinically detect-
able abnormalities (tenderness, and/or swelling of the joints).
Joints were assessed for the presence of bone erosion, synovial
effusion, and joint effusions. Hypertrophy of the synovial
membrane of the knee was detected in ﬁve patients (12.5%).
However it was also detected in the MCP joints of nine pa-
tients (22.5%) (Fig. 2). Knee joint effusion was detected in 5
patients (12.5%) (Fig. 3), and sporadic tendenitis was detected
in 10 (25%) patients.Figure 3 (A) longitudinal ultrasound of the knee shows joint
effusion, (B) following compression with the probe, ﬂuid is
squeezed into parts of the joint so the effusion is compressible,
distinguishes it from synovitis.
Table 5 Comparison of the levels of CXCl3 between patients with and without synovial hypertrophy.
Level of CXCL13 Patients with synovial hypertrophy Patients without synovial hypertrophy T P Sig
Mean ± SD 250.45 ± 60.82 200.41 ± 70.15 2.25 0.03 S
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synovial hypertrophy (knees and MCPs) and those without,
there was a signiﬁcant difference as seen below (P< 0.03).
Testing the association of level of CXCL 13 and synovial mem-
brane hypertrophy (R 0.27), (P< 0.003) a signiﬁcant associa-
tion was found (Table 5).
4. Discussion
Egypt has a high prevalence of antibodies to hepatitis C virus
(HCV), estimated nationally at 14.7%. Numerous HCV prev-
alence studies in Egypt have published various estimates from
different Egyptian communities. Incidence from the previous
community studies was 6.9/1000 per person per year. More
than 500,000 new HCV infections per year were estimated.
Iatrogenic transmission is the most likely way of transmis-
sion.13 Clinical sequels of HCV account for a signiﬁcant pro-
portion of patients presenting to the hepatologist with well
described manifestations of hepatitis C including; hepatomeg-
aly, cirrhosis, lower limb edema, ascites and even hepatocellu-
lar carcinoma. The extrahepatic manifestations of hepatitis C
infection, though common, are less well appreciated as re-
corded by Sterling and Bralow in 2006 where they stated that
36% of their studied group had extrahepatic manifestations.
The most prevalent extrahepatic manifestations are the rheu-
matologic manifestations; fatigue, arthralgia and essential
mixed cryoglobulinemia.14 These various rheumatological
symptoms have no speciﬁc pattern fulﬁlling the diagnostic cri-
teria of the American college of Rheumatology (ACR).
Although HCV is a hepatotropic virus, in some patients the
primary manifestations of infection occur outside the liver, as
autoimmune manifestations, which can be dominant, whereas
the hepatic disease can be quiescent or mild.15
This work was designed to study the rheumatologic mani-
festations of HCV. Our results showed that the overall preva-
lence of any rheumatic manifestations was 85%, which is
similar to the results of Stefanova–Petrova et al.16 who found
76% of the studied Bulgarian patients who had at least one
extrahepatic manifestation. However their clinical manifesta-
tions were not in accordance with our results except for Ray-
naud’s phenomenon; (11.8% vs. 10%). Our results were also
similar to the results of Sadek et al. in 200317, where they sta-
ted that the overall prevalence of rheumatologic manifesta-
tions was 89.3% in a study of 75 Egyptian patients with
chronic HCV in El-Minia region. Our results were higher than
those of Mohammed et al.18 where they reported that the over-
all estimated prevalence of rheumatologic manifestations was
16.39% in their study of 306 Egyptian patients with HCV
attending the National Hepatology and Tropical Medicine Re-
search Institute. Our higher prevalence of the overall rheuma-
tologic manifestations could be explained; as most of the
selected cases in this study were chosen from those attending
or referred to the Rheumatology clinic, and also the long
standing disease process as 32% of our studied patients had
liver cirrhosis. Arthralgia was the commonest extrahepaticmanifestation, followed by myalgia, ﬁbromyalgia, and chronic
fatigue. These results are in accord with other studies.11,16–18
Buskila et al. also reported that rheumatologic manifestations
of HCV infection are common and include, myalgia, arthritis,
and ﬁbromyalgia and sicca symptoms, and the most commonly
involved joints were; metacarpophalangeal, proximal, inter-
phalangeal, wrist, shoulder, and knees, which are similar to
our results.19,20
As regards HCV-related arthropathy; it commonly presents
as symmetrical inﬂammatory arthritis involving small joints.
The joints involved are similar to rheumatoid arthritis (RA).
This sometimes makes it difﬁcult to differentiate true RA from
HCV patients with a positive rheumatoid factor but without
RA.
In our study, 35% of our patients had symmetrical small
joint affection of the hands, this result was in agreement with
Zuckerman et al.21 and Nyigni et al. in 2010.22 Differentiating
HCV-related arthropathies from classic RA is essential. In
contrast to patients who have RA, our patients experienced
minimal morning stiffness, did not exhibit rheumatoid nodules
and there was no evidence of erosive arthritis. Anti ccp anti-
bodies were not done, however it is a deﬁnite lab test to distin-
guish RA from HCV associated arthropathies and we should
recommend it to be done in further similar studies.
Ultrasound is a promising tool for musculoskeletal assess-
ment of patients with rheumatologic manifestations. Ultra-
sound has a particular advantage that an experienced
observer can rapidly screen several joints in a relatively short
time.23 Positive ﬁndings were detected in 26 (85%) of our
HCV patients. None of our patients had erosion arthritis, this
was in agreement with Nyingi et al. in 201022 who concluded
that no radiological features distinguish HCV-related arthritis
from arthritis caused by other disorders. However, an impor-
tant clinical characteristic of HCV-related arthropathy is the
lack of bone erosions on imaging; therefore, imaging is essen-
tial in the diagnostic workup to evaluate for other causes of
arthritis. Neither synovial ﬂuid analysis nor synovial tissue
biopsy has been useful in the diagnosis of HCV-related
arthropathy; ultimately, this is a diagnosis of exclusion.22,23
As regards our laboratory and immunological results, they
were similar to the results of Saadoun et al. in 200724 who sta-
ted that circulating mixed cryoglobulins (MC) are present in
40–60% of HCV-infected patients, this is also augmented by
old studies which showed that mixed cryoglobulinemia has a
clinically signiﬁcant association with chronic HCV infection,
particularly in those with long duration of liver disease and cir-
rhosis.25,26 MCs reﬂect the expansion of B cells producing a
pathogenic IgM with rheumatoid factor (RF) activity. Its
expression can be variable including palpable purpura, cutane-
ous vasculitis, arthralgias, neuropathy or Raynaud’s phenom-
enon. This was shown in our study, where we found 80% of
patients with +ve cryoglobulins expressed rheumatologic ﬁnd-
ings, although it did not show a signiﬁcant difference from the
control group, yet it could be due to the low cryocrit percent as
stated by Leone et al.27 where they found 51/114 (44.7%)
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matological symptoms and the mean cryocrit value in these pa-
tients was 2.6%, while in patients with HCV infection with
MC without rheumatological symptoms the cryocrit value
was lower than 0.5% in 50% of cases.27
The third component of human complement (C3) plays a
central role in innate immune function as its activation is re-
quired to trigger classical as well as alternative complement
pathways. This complement system has been shown to contrib-
ute to the protection of the host from virus infection.28,29
In this study, we observed that sera from patients chroni-
cally infected with HCV displayed signiﬁcantly lower C3 and
C4 levels than sera from controls, which agrees with another
study which demonstrated that sera from patients chronically
infected HCV displayed signiﬁcantly lower C3 levels than sera
from healthy individuals and also liver biopsy specimens from
the same patients also exhibited lower C3 mRNA expression
than liver tissues from healthy donors.29,30
HCV plays a critical role in a wide variety of inﬂammatory
processes by regulating the expression of transcriptional fac-
tors and proinﬂammatory genes, including tumor necrosis fac-
tor and members of its superfamily, interleukins, and
chemokines.31 Chemokines have been shown to orchestrate
migration and preferential sequestration of B and T cells in
HCV-infected compartments. Indeed, an increased number
of circulating B cells has been demonstrated in these patients,
probably reﬂecting deregulation of B-cell trafﬁc. The homeo-
static trafﬁcking of B cells is mainly regulated by the chemo-
kine CXCL13 through interaction with CXCR5, its only
known receptor, expressed on all mature circulating B cells
and on a subset of memory CD4 T cells.32
MC is a systemic small-vessel vasculitis; B-cell expansion is
the biological substrate of the disease. It can be regarded as a
benign lymphoproliferative condition that may evolve into
frank lymphoma. HCV infection is the main causative factor
of MC,33 HCV lymphotropism is responsible for poly-
oligoclonal B-lymphocyte expansion with a consequent pro-
duction of different autoantibodies and immune-complexes,
including cryoglobulins, which are characterized by the coexis-
tence of autoimmune and lymphoproliferative alterations.
Therefore, it represents the prototype of HCV-associated dis-
orders.34 Moreover the most frequent and clinically important
endocrine HCV related extrahepatic diseases (HCV-EHDs) are
thyroid disorders. However none of our patients showed
thyroid disorders. A possible common immunological Th1
pattern could be the pathophysiological base of the association
of HCV-EHDs, with thyroid autoimmunity. In fact, HCV
infection of thyrocytes may act by upregulating CXCL10
secretion in these cells that is responsible for Th1 lymphocyte
recruitment. Th1 response leads to increased IFNc and TNFa
production that in turn stimulates CXCL10 secretion by the
target cells, thus perpetuating the immune cascade. This pro-
cess may lead to the appearance of thyroid autoimmune disor-
ders in genetically predisposed subjects.35
In this study, serum CXCL13 levels were found to be ele-
vated in chronic HCV infection compared with healthy con-
trols with the highest levels found in HCV-infected
cryoglobulinemic patients, and in patients with articular syno-
vial hypertrophy with a signiﬁcant association with synovial
hypertrophy. Both of these results conﬁrm the coexistence of
both autoimmune and lymphoproliferative alterations of
chronic HCV (indicated in group A by the presence of livercirrohsis and ascitis) associated disorders as described in previ-
ous studies.33,36 A similar study found levels of CXCL13 were
signiﬁcantly higher in RA compared to healthy controls and
correlated with measures of synovitis, which emerged as a
new biological marker in early RA, accurate in assessing the
severity of synovitis.37 These high serum levels of CXCL13
may be a consequence of high local production, which is a per-
petuation of the augmented autoimmune (manifested as MC)
and lymphoproliferative state (manifested as synovial hyper-
trophy and musculoskeletal manifestations) induced by the
ongoing chronic hepatic inﬂammation, which maintains the
pathologic process in tissues by attracting additional lympho-
cytes and more B cell proliferation and over production of
CXCL 13 leading to chronic damage.38
5. Conclusion
In this study, serum CXCL13 levels were found to be elevated
in chronic HCV infection compared with healthy controls.
High levels correlated with HCV extrahepatic musculoskeletal
manifestations with mixed cryoglobulinemia and were signiﬁ-
cantly associated with articular synovial hypertrophy.
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